P27Kip1: Regulation and function of a cell cycle key regulator

Biotecnologia Aplicada

Volumn 18, Issue 4, 2002, Pages 193-202

  Moro, Alejandro ^a   Santos, Alicia ^a   Morera Díaz, Yanelys ^a   Perea, Silvio E ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

Apoptosis; Cell cycle; Cyclin dependent kinase inhibitor; p27Kip1; Progression in G1

Indexed keywords

CYCLIN D; CYCLIN DEPENDENT KINASE 2; PROTEIN P27;

APOPTOSIS; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; COMPLEX FORMATION; CONTACT INHIBITION; DOWN REGULATION; HUMAN; MITOSIS; ONCOGENE; PROTEIN ANALYSIS; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; TUMOR;

MAMMALIA; PYRONIA TITHONUS;

EID: 0035497630     PISSN: 08644551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13(12):1501-12.
2. Kato J. Induction of S phase by G1 regulatory factors. Front Biosci 1999;4:D787-92.
3. Nevins JR. The R8/E2F pathway and cancer. Hum Mol Genet 2001;10(7):699-703.
4. Bortek J, Lukas J. Pathways governing G1/S transition and their response to DNA domage. FEBS Lett 2001;490(3):117-22.
5. Tsihlias J, Kapusto L, Slingerland J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med 1999;50:401-23.
6. Rocco JW, Sidransky D. p16 (MTS-1/CDKN2/INK4o) in cancer progression. Exp Cell Res 2001;264(1):42-55.
7. Cornero A, Hannon GJ. The INK4 family of CDK inhibitors. Curt Top Microbiol Immunol 1998;227:43-55.
8. Kip1 regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res 2001;264(1):148-68.
9. John RM, Ainscough JF, Barton SC, Surani MA. Distant cis-elements regulate imprinted expression of the mouse p57 (Kip2) (Cdkn1c) gene: implications for the human disorder, Beckwith-Wiedemann syndrome. Hum Mol Genet 2001;10(15):1601-9.
10. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366(6456):704-7.
11. INK4B is a patentiol effector of TGF-beta-induced cell cycle arrest. Nature 1994;371(6494):257-61.
12. Guon KL, Jenkins CW, Li Y, Nichols MA, Wu X, O'Keefe CL, et al. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 1994; 8(24):2939-52.
13. ink4. Mol Cell Biol 1995;15(5):2682-8.
14. Xiong Y, Hannon GJ, Zhong H, Cosso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 66(6456):701-4.
15. El-Deiry WS, Takino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75(4):817-25.
16. Noda A, Ning Y, Venoble SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994;211(1):90-8.
17. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;78(1):59-66.
18. KIP2 a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995;9(6):639-49.
19. Kip1 and its alterations in tumor cells: a review. J Cell Physiol 2000;183(1):18-27.
20. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000;183(1):10-7.
21. Kobayashi H, Montgomery KT, Bohlander SK, Adro CN, Lim BL, Kucherlapoti RS, et al. Fluorescence in situ hybridization mapping of translocations and deletions involving the short arm of human chromosome 12 in malignant hematologic diseases. Blood 1994; 84(10):3473-82.
22. Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res 1995;55(6):1206-10.
23. Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 1995;55(6):1211-4.
24. Tayashima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994;78(1):67-74.
25. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995;9(10):1149-63.
26. Maraianu J. Nuclear import and export pathways. J Cell Biochem 1999;Suppl 32-33:76-83.
27. Kip1, a cyclin-dependent kinase inhibitor. Biochem Biophys Res Commun 200;274(1):37-42.
28. Reynisdottir I, Massagué J. The subcellular locations of p15 (Ink4b) and p27 (Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev 1997;11(4):492-503.
29. Müller D, Thieke K, Burgin A, Dickmanns A, Eilers M. Cyclin E-mediated elimination of p27 requires its interaction with the nuclear pare-associated protein mNPAP60. EMBO J 2000; 19(10):2168-80.
30. Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 1996; 382(6589):325-31.
31. Yang W, Shen J, Wu M, Arsuro M, FitzGerald M, Suldan Z, et al. Repression of transcription of the p27 [Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene 2001; 20(14):1688-702.
32. Kip1 in cell cycle arrest after androgen depletion in mouse mammary carcinoma cells (SC-3). Oncogene 1998;17(20):2619-27.
33. Kip1 mRNA in IFN-sensitive and resistant cell lines. Biochem Biophys Res Commun 1998;245(3):752-6.
34. Gardner LB, Li Q, Park MS, Flanagan WM, Semenzo GL, Dong CV. Hypoxia inhibits G1/S transition through regulation of p27 expression. J Biol Chem 2001;276(11):7919-26.
35. Kip1 expression. J Biol Chem 2000;275(32):24500-5.
36. Kip1 gene promoter. FEBS Lett 1997;411(1):1-6.
37. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formotion by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999;96(8):4240-5.
38. Kip1. Mol Cell Biol 2000;(24):9138-48.
39. Kip1 gene promoter that lacks vitamin D response elements. J Biol Chem 1999;274(45):32309-17.
40. Kip1 promoter by IFNalpha 2b. Biochem Biophys Res Commun 2000;269(1):31-4.
41. Kip1 expression in rodent pituitary cell lines. Am J Pathol 1998; 153(5):1475-82.
42. Kip2 transgene is not activated by passage through the maternal mouse germline. Hum Mol Genet 1999;8(12):2211-9.
43. Cost GJ, Thompson JS, Reichard BA, Lee JY, Feinberg AP. Lack of imprinting of three human cyclin-dependent kinase inhibitor genes. Cancer Res 1997;57(5):926-9.
44. Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3(2):227-30.
45. Lada M, Cukor B, Tom SW, Lavin P, Fiorentino M, Droetto GF, et al. Increased proteosome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectol carcinomas. Not Med 1997;3(2):231-4.
46. Kip1 expression in nontumorous and neoplastic human pituitaries. Am J Pathol 1997;151(2):509-19.
47. Millard SS, Vidal A, Markus M, Koff A. A Urich element in the 5′ untranslated region is necessary for the translation of p27 mRNA. Mol Cell Biol 2000;20(16):5947-59.
48. Miskimins WK, Wang G, Hawkinson M, Miskimins R. Control of cyclin-dependent kinase inhibitor p27 expression by cap-independent translation. Mol Cell Biol 2001;21(15):4960-7.
49. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994b;8(1):9-22.
50. Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994;372(6506):570-3.
51. Kip1 for restriction point control of the fibroblast cell cycle. Science 1996;272(5263):877-80.
52. Levenberg S, Yarden A, Kam Z, Geiger B. p27 is involved in N-cadherin-mediated contact inhibition of cell growth and S-phase entry. Oncogene 1999;18(4):869-76.
53. Fang F, Orend G, Watanabe N, Hunter T, Ruoslahti E. Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science 1996;271(5248):499-502.
54. Reynisdottir I, Polyak K, Iavarone A, Massagué J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev 1995;9(15):1831-45.
55. Kip1 of cyclin-dependent kinase 4 activation. Cell 1994;79(3):487-96.
56. Kip1 in a human gastric carcinoma cell line. Cell Growth Differ 1997;8(1):47-52.
57. Kip1 in gamma interferon-mediated growth arrest of mammary epithelial cells and related defects in mammary carcinoma cells. Oncogene 1997;14(17):2111-22.
58. Kip1. Oncogene 1999; 18(25):3742-53.
59. Kip1 degradation in HepG2 cells. Oncogene 2000;19(32):3675-83.
60. Kip1 regulation of the G1-phase traverse in 1,25-dihydroxyvitamin D3-treated HL60 cells. Cancer Res 1997;57(14):2851-5.
61. Hengst L, Dulic V, Slingerland JM, Lees E, Reed SI. A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci USA 1994;91(12):5291-5.
62. Weng LP, Brown JL, Eng C. PTEN coordinotes G1 arrest by down-regulating cyclin D1 via its protein phosphotase activity and up-regulating p27 via its lipid phosphotase activity in a breast cancer model. Hum Mol Genet 2001;10(6):599-604.
63. Foster JS, Henley DC, Bukovsky A, Seth P, Wimalaseno J. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function. Mol Cell Biol 2001; 21(3):794-810.
64. Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci USA 2000;97(16):9042-6.
65. Reichert TE, Nagashima S, Kashii Y, Stanson J, Goo G, Dou QP, Whiteside TL. Interleukin-2 expression in human carcinoma cell lines and its role in cell cycle progression. Oncogene 2000;19(4):514-25.
66. kip1 synthesis by platelet-derived growth factor in BALB/c 3T3 cells. Mol Cell Biol 1996;16(8):4327-36.
67. Sgambato A, Flamini G, Cittadini A. New prognostic factors in oncology. Rays 1996; 21(4):559-72.
68. Kip1. Mol Cell Biol 1997; 17(7):3850-7.
69. Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene 1997;15(6):629-37.
70. kip1 downregulation, passage through the restriction point, and entry into S phase in growth factor-stimulated NIH 3T3 fibroblasts. Mol Cell Biol 1997;17(9):5348-58.
71. Kip1 mislocalization. Oncogene 2000; 19(51):5926-35.
72. Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J Biol Chem 2000;275(50):39223-30.
73. Kip1 from cyclin E/cyclin-dependent kinase (CDK) 2 but not from cyclin D1/CDK4 complexes in cells transformed by polyamine biosynthetic enzymes. Cancer Res 2000;60(18):5244-53.
74. Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J Biol Chem 1997;272(1):13-6.
75. Shirane M, Harumiya Y, Ishida N, Hirai A, Miyamoto C, Hatakeyama S, et al. Down-regulation of p27 (Kip1) by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J Biol Chem 1999;274(20):13886-93.
76. Montagnoli A, Fiore F, Eyton E, Carrano AC, Draetta GF, Hershko A, Pagano M. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes and Dev 1999; 13(9):1181-9.
77. Kip1 is instigated by Job1. Nature 1999; 398(6723):160-5.
78. Kip1 levels by the cyclin encoded by Koposi's sorcoma-associated herpesvirus. EMBO J 1999;18(3):654-63.
79. Kip1. Genes Dev 1997;11(11):1464-78.
80. Pagano M, Tom SW, Theodoros AM, Beer-Romero P, Del Sol G, Chou V, et al. Role of the ubiquitin-proteosome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269(5224):682-5.
81. Kip1 in a human lung cancer cell line. Oncol Rep 2001;8(2):425-9.
82. Scheffner M, Huibregtse JM, Vierstro RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993;75(3):495-505.
83. Thanos D, Maniatis T. NF-kappa B: a lesson in family values. Cell 1995;80(4):529-32.
84. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997;16(13):3797-804.
85. Ciechanover A. Ubiquitin-mediated degradation of cellular proteins: why destruction is essential for construction, and how it got from the test tube to the patient's bed. Isr Med Assoc J 2001;3(5):319-27.
86. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999;1(4):193-9.
87. Carrano AC, Pagano M. Role of the F-box protein Skp2 in adhesion-dependent cell cycle progression. J Cell Biol 2001;153(7):1381-90.
88. Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. p27 (Kip1) ubiquitination and degradation is regulated by the SCF (Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 1999;9(12):661-4,
89. SKP2. Current Biology 2001;11 (4):263-7.
90. Kip1 by ubiquitination. Proc Natl Acad Sci USA 2000;97(9):4579-84.
91. Darbon JM, Devoult A, Tavioux S, Fesquet D, Martinez AM, Galas S, et al. Cloning, expression and subcellular localization of the human homolog of p40MO15 catalytic subunit of cdk-activating kinase. Oncogene 1994;9(11):3127-38.
92. Chomovitz DA, Segal D. JAB1/CSN5 and the COP9 signalosome. A complex situation. EMBO Rep 2001;2(2):96-101.
93. Kip1. J Biol Chem 2001; 276(15):12084-90.
94. Kip1, increases its protein stability. J Biol Chem 2000;275(33):25146-54.
95. Takeuchi S, Bartrom CR,Wado M, Reiter A, Hatto Y, Seriu T, et al. Allelotype analysis of childhood acute lymphoblastic leukemia. Cancer Res 1995;55(22):5377-82.
96. Hatta Y, Takeuchi S, Yokata J, Koeffler HP. Ovarian cancer has frequent loss of heterozygosity at chromosome 12p12.3-13.1 (region of TEL and Kip1 loci) and chromosome 12q23-ter: evidence for two new tumour-suppressor genes. Br J Cancer 1997;75(9):1256-62.
97. Kibel AS, Freije D, Isaacs WS, Sova GS. Deletion mapping at 12p12-13 in metastatic prostate cancer. Genes Chromosomes Cancer 1999;25(3):270-6.
98. Kawamoto N, Morosetti R, Miller CW, Pork D, Spirin KS, Nakamoki T, et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 1995;55(11):2266-9.
99. Kip1 mutation found in breast cancer. Cancer Res 1996;56(10):2400-4.
100. kip1 in primary breast carcinomas. Hum Genet 1996;97(1):91-4.
101. KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. Blood 1995;86(5):1924-30.
102. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27 (Kip1)-deficient mice. Cell 1996;85(5):733-44.
103. Kiyakawa H, Kineman RD, Manova-Tadorova KO, Soares VC, Hoffman ES, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27 (Kip1). Cell 1996;85(5):722-32.
104. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, et al. Mice lacking p27 (Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996;85(5):707-20.
105. Karnezis AN, Dorokhov M, Grompe M, Zhu L. Loss of p27Kip1 enhances the transplantation efficiency of hepatocytes transferred into diseased livers. J Clin Invest 2001; 108(3):383-90.
106. kip1. Nat Med 2000;6(11):1235-40.
107. zur Hausen H. Cervical carcinoma and human papillomovirus: on the rood to preventing a major human cancer. J Natl Cancer Inst 2001;93(4):252-3.
108. McMurray HR, Nguyen D, Westbrook TF, McAnce DJ. Biology of human papilla-maviruses. Int J Exp Pathol 2001;82(1):15-33.
109. KIP1 by the human papillomovirus type 16 E7 oncoprotein. Oncogene 1996;13(11):2323-30.
110. Kip1 by the viral E1A oncoprotein in TGFβ-treated cells. Nature 1996;380(6571):262-5.
111. Kip1. EMBO J 1998;17(20):5987-97.
112. Schuchner S, Wintersberger E. Binding of polyomavirus small T antigen to protein phosphatase 2A is required for elimination of p27 and support of S-phase induction in concert with large T antigen. J Virol 1999;73(11): 9266-73.
113. Swanton C, Jones N. Strategies in subversion: de-regulation of the mammalian cell cycle by viral gene products. Int J Exp Pathol 2001;82(1):3-13.
114. LoBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sondhu C, Chou HS, et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev 1997;11(7):847-62.
115. Parry D, Mahony D, Wills K, Lees E. Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors. Mol Cell Biol 1999;19(3):1775-83.
116. Kip1 CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 1999;18(6):1571-83.
117. Kip1 activity. Mol Cell Biol 1999;19(10):7011-9.
118. Evon GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411(6835):342-8.
119. Kotoyose Y, Kim M, Rokkor AN, Li Z, Cowon KH, Seth P. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 1997;57(24):5441-5.
120. Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene 1997;14(19):2283-9.
121. Fujiedo S, Inuzuko M, Tonoko N, Sunogo H, Fon GK, Ito T, et al. Expression of p27 is associated with Bax expression and spontaneous apaptosis in oral and orophoryngeal carcinoma. Int J Cancer 1999;84(3):315-20.
122. Kip1 on resistance of tumor cells to anticancer agents. Nat Med 1996;2(11):1204-10.
123. KIP1 to the confluence-dependent resistance of HT29 human colon carcinoma cells. Int J Cancer 1998;77(5):796-802.
124. Kip1 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procospose-3 activation in leukemic cells. Oncogene 1999;18(7):1411-8.
125. Mosudo A, Osoda H, Yotabe Y, Kozoki K, Totemotsu Y, Tokohoshi T, et al. Protective function of p27 (KIP1) against apoptosis in small cell lung cancer cells in unfavorable microenvironments. Am J Pathol 2001;158(1):87-96.
126. Kip1 mediates apaptosis in endothelial cells through activation of Cdk2: role of a caspase cascade. Mol Cell 1998;1(4):553-63.
127. Kip1 mediates its anti-opoptotic activity. Oncogene 1999;18(34):4839-47.
128. KiP1 overexpression inhibits the growth and doxorubicin sensitivity of HT29 human colon cancer cells in vivo. Anticancer Res 2000;20(2A):849-52.
129. kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000; 19(38):4319-27.
130. Sethi T, Rintoul RC, Moore SM, MocKinnon AC, Solter D, Chao C, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999;5(6):662-8.